{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:55:28Z","timestamp":1785776128950,"version":"3.56.0"},"reference-count":48,"publisher":"The Journal of Rheumatology","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,3,29]]},"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:p>Although statin-induced muscle toxicity was recognized, a subset of patients presented with severe, persistent necrotizing myopathy despite statin withdrawal. Recognized initially through the serendipitous aggregation of cases in the longitudinal myositis cohort at the Johns Hopkins Myositis Center, the anti\u20133-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody was identified in patients with previously seronegative necrotizing myopathy who shared a significant history of statin exposure. The autoantigen is the statin\u2019s pharmacological target, providing a specific biomarker and a compelling mechanistic link to the drug. Subsequent investigation has delineated a complex, self-perpetuating pathogenesis, in which statin exposure upregulates HMGCR expression on regenerating muscle fibers in genetically susceptible individuals, sustaining the autoimmune response. Pathogenic IgG antibodies drive myofiber necrosis through complement activation on the myofiber surface, and recent evidence indicates that internalized autoantibodies disrupt HMGCR function, leading to pathological lipid accumulation and necrosis. Curiously, the disease also occurs in statin-na\u00efve patients, including children, where it can clinically mimic muscular dystrophy, and the trigger remains unknown. HLA-DRB1*11:01 is a strongly associated risk allele, and certain Indigenous populations have been shown to be at a substantially increased risk. Anti-HMGCR myopathy is distinguished from self-limited toxic myopathy by its persistence\u2014generally presenting years rather than weeks or months after stain exposure\u2014and its response to immunotherapy. Intravenous Ig and rituximab are cornerstone treatments, with emerging therapies targeting the neonatal Fc receptor. Targeting complement in a clinical trial yielded unexpected negative results. This review traces the scientific journey from a clinical conundrum to a paradigm-shifting discovery, highlighting key milestones and future directions.<\/jats:p>","DOI":"10.3899\/jrheum.2026-0305","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:20:17Z","timestamp":1778847617000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["From Serendipity to Science: How Anti-HMGCR Antibodies Changed Our Understanding of Myositis"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-7306","authenticated-orcid":false,"given":"Lisa","family":"Christopher-Stine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026080309301654000_53.Suppl_1.1.1","first-page":"282","article-title":"[Case of a rare muscle disease]. [Article in German]","volume":"4","author":"Wagner","year":"1863","journal-title":"Arch Heilkd Leipz"},{"key":"2026080309301654000_53.Suppl_1.1.2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1206170"},{"key":"2026080309301654000_53.Suppl_1.1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2026080309301654000_53.Suppl_1.1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2026080309301654000_53.Suppl_1.1.5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/path.1710970204","article-title":"Skeletal muscle necrosis associated with cainoma","volume":"97","author":"Smith","year":"1969","journal-title":"J Pathol"},{"key":"2026080309301654000_53.Suppl_1.1.6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology"},{"key":"2026080309301654000_53.Suppl_1.1.7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4103\/0028-3886.232296","article-title":"Idiopathic inflammatory myopathies in adults: a comparative study of Bohan and Peter and European Neuromuscular Center 2004 criteria","volume":"66","author":"Challa","year":"2018","journal-title":"Neurol India"},{"key":"2026080309301654000_53.Suppl_1.1.8","first-page":"66","article-title":"The $10 billion pill","volume":"147","author":"Simons","year":"2003","journal-title":"Fortune"},{"key":"2026080309301654000_53.Suppl_1.1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006"},{"key":"2026080309301654000_53.Suppl_1.1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.10.007"},{"key":"2026080309301654000_53.Suppl_1.1.11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21486"},{"key":"2026080309301654000_53.Suppl_1.1.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.27572"},{"key":"2026080309301654000_53.Suppl_1.1.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156"},{"key":"2026080309301654000_53.Suppl_1.1.14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041367"},{"key":"2026080309301654000_53.Suppl_1.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.037"},{"key":"2026080309301654000_53.Suppl_1.1.16","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"2026080309301654000_53.Suppl_1.1.17","doi-asserted-by":"crossref","first-page":"e248880","DOI":"10.1136\/bcr-2022-248880","article-title":"Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy","volume":"15","author":"Adler","year":"2022","journal-title":"BMJ Case Rep"},{"key":"2026080309301654000_53.Suppl_1.1.18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/L17-0620","article-title":"Immune-mediated necrotizing myopathy and dietary sources of statins","volume":"168","author":"Barbacki","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026080309301654000_53.Suppl_1.1.19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000523"},{"key":"2026080309301654000_53.Suppl_1.1.20","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.42126","article-title":"Increased risk of statin-associated autoimmune myopathy among American Indians","volume":"74","author":"Wei","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026080309301654000_53.Suppl_1.1.21","doi-asserted-by":"crossref","first-page":"152759","DOI":"10.1016\/j.semarthrit.2025.152759","article-title":"Statin-associated immune-mediated necrotizing myopathy in Hispanic Americans","volume":"73","author":"Dinh","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026080309301654000_53.Suppl_1.1.22","doi-asserted-by":"crossref","first-page":"keaf618","DOI":"10.1093\/rheumatology\/keaf618","article-title":"Increased prevalence and incidence of statin-associated immune-mediated necrotizing myopathy in Native Americans","volume":"65","author":"Dinh","year":"2026","journal-title":"Rheumatology"},{"key":"2026080309301654000_53.Suppl_1.1.23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/keaa337","article-title":"Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies","volume":"60","author":"Close","year":"2021","journal-title":"Rheumatology"},{"key":"2026080309301654000_53.Suppl_1.1.24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/rheumatology\/keae282","article-title":"Anti-HMGCR myopathy: estimated 5-fold higher incidence in Polynesian compared with European populations in Aotearoa\/New Zealand","volume":"64","author":"Chow","year":"2025","journal-title":"Rheumatology"},{"key":"2026080309301654000_53.Suppl_1.1.25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res Hoboken"},{"key":"2026080309301654000_53.Suppl_1.1.26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24642"},{"key":"2026080309301654000_53.Suppl_1.1.27","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"2026080309301654000_53.Suppl_1.1.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213518"},{"key":"2026080309301654000_53.Suppl_1.1.29","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026080309301654000_53.Suppl_1.1.30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/ard-2024-225732","article-title":"Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy","volume":"84","author":"Tiniakou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026080309301654000_53.Suppl_1.1.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225773"},{"key":"2026080309301654000_53.Suppl_1.1.32","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.ard.2025.04.027","article-title":"In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis","volume":"84","author":"Giannini","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026080309301654000_53.Suppl_1.1.33","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/mus.70016","article-title":"The effect of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) human autoantibodies on muscle regeneration in mice","volume":"72","author":"Julien","year":"2025","journal-title":"Muscle Nerve"},{"key":"2026080309301654000_53.Suppl_1.1.34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2026080309301654000_53.Suppl_1.1.35","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.81a.13158"},{"key":"2026080309301654000_53.Suppl_1.1.36","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.autrev.2023.103464","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review","volume":"22","author":"Kilinc","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026080309301654000_53.Suppl_1.1.37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy","volume":"37","author":"Kruse","year":"2022","journal-title":"J Clin Apher"},{"key":"2026080309301654000_53.Suppl_1.1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"2026080309301654000_53.Suppl_1.1.39","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamainternmed.2025.3862","article-title":"Polymyositis masking statin-induced necrotizing autoimmune myopathy: a teachable moment","volume":"185","author":"Chang","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026080309301654000_53.Suppl_1.1.40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28114","article-title":"Management of immune-mediated necrotizing myopathy","volume":"70","author":"Suh","year":"2024","journal-title":"Muscle Nerve"},{"key":"2026080309301654000_53.Suppl_1.1.41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/mus.28333","article-title":"Effectiveness and safety of IVIG for the treatment of HMGCR immune-mediated necrotizing myopathy","volume":"71","author":"Suh","year":"2025","journal-title":"Muscle Nerve"},{"key":"2026080309301654000_53.Suppl_1.1.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515161"},{"key":"2026080309301654000_53.Suppl_1.1.43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40674-025-00239-5","article-title":"Treatment algorithms for inflammatory myopathies in adults: from guidelines to clinical practice","volume":"11","author":"Selva-O\u2019Callaghan","year":"2025","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2026080309301654000_53.Suppl_1.1.44","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.3390\/jcm9113454","article-title":"Efficacy and safety of high-dose immunoglobulin-based regimen in statin-associated autoimmune myopathy: a multi-center and multi-disciplinary retrospective study","volume":"9","author":"Treppo","year":"2020","journal-title":"J Clin Med"},{"key":"2026080309301654000_53.Suppl_1.1.45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.0000000000201315","article-title":"Pearls & oy-sters: managing cholesterol in a patient with statin intolerance due to anti-HMG-CoA reductase\u2013associated myopathy","volume":"99","author":"Villa","year":"2022","journal-title":"Neurology"},{"key":"2026080309301654000_53.Suppl_1.1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w"},{"key":"2026080309301654000_53.Suppl_1.1.47","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026080309301654000_53.Suppl_1.1.48","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.3390\/biomedicines10082036","article-title":"Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model","volume":"10","author":"Julien","year":"2022","journal-title":"Biomedicines"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:30:37Z","timestamp":1785774637000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":48,"journal-issue":{"issue":"Suppl 1","published-online":{"date-parts":[[2026,8,1]]},"published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.3899\/jrheum.2026-0305"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0305","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}